Search results for "Liver Transplantation."

showing 10 items of 354 documents

Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy

2020

Abstract Background and aims Nonalcoholic steatohepatitis (NASH) may progress to advanced liver disease (AdvLD). This study characterized comorbidities, healthcare resource utilization (HCRU) and associated costs among hospitalized patients with AdvLD due to NASH in Italy. Methods and results Adult nonalcoholic fatty liver disease (NAFLD)/NASH patients from 2011 to 2017 were identified from administrative databases of Italian local health units using ICD-9-CM codes. Development of compensated cirrhosis (CC), decompensated cirrhosis (DCC), hepatocellular carcinoma (HCC), or liver transplant (LT) was identified using first diagnosis date for each severity cohort (index-date). Patients progres…

Liver CirrhosisMaleTime FactorsCirrhosisDatabases FactualEndocrinology Diabetes and MetabolismMedicine (miscellaneous)ComorbidityHospital Cost030204 cardiovascular system & hematologyLiver diseasePatient Admission0302 clinical medicineRetrospective StudieNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseaseAmbulatory CarePrevalenceMedicineHospital Costseducation.field_of_studyDrug CostNutrition and DieteticsLiver NeoplasmsNASHMiddle AgedPrognosisItalyLiver NeoplasmHepatocellular carcinomaCohortDisease ProgressionHealth ResourcesFemaleCardiology and Cardiovascular MedicineHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularTime FactorAdolescentCostPrognosiLiver CirrhosiPopulation030209 endocrinology & metabolismPharmacyDrug CostsYoung Adult03 medical and health sciencesNAFLDInternal medicineHumanseducationAgedRetrospective StudiesHealth Resourcebusiness.industryRisk Factormedicine.diseaseComorbiditydigestive system diseasesLiver TransplantationHCRUbusinessAdministrative Claims HealthcareNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Haemophagocytic syndrome in a liver transplant patient during treatment with Telaprevir.

2013

Haemophagocytic syndrome (HS) is a rare disease that is often fatal despite treatment. HS is characterized by fevers, lymphadenopathy, hepatosplenomegaly, cytopenias and hyperferritinaemia due to deregulated activation and proliferation of macrophages, leading to uncontrolled phagocytosis of platelets, erythrocytes, lymphocytes, and their hematopoietic precursors throughout the reticuloendothelial system. Mycobacterium tuberculosis-associated HS is a rare and underdiagnosed association with only 39 cases reported. We describe a case of HS associated with disseminated Mycobacterium tuberculosis in the setting of post-liver transplantation anti-hepatitis C therapy with pegylated interferon (p…

Liver CirrhosisMaleTuberculosisTime Factorsmedicine.medical_treatmentHepatosplenomegalyAntitubercular AgentsSpecialties of internal medicineHepacivirusLiver transplantationVHCAntiviral AgentsLymphohistiocytosis HemophagocyticTelaprevirTelaprevirchemistry.chemical_compoundFatal OutcomePegylated interferonRisk FactorsmedicineHumansTuberculosisHepatologyHaemophagocytic syndromebusiness.industryRibavirinGeneral MedicineMycobacterium tuberculosisMiddle Agedmedicine.diseaseHepatitis CLiver TransplantationTransplantationchemistryRC581-951ImmunologyDrug Therapy CombinationVirus Activationmedicine.symptombusinessOligopeptidesImmunosuppressive Agentsmedicine.drugRare diseaseAnnals of hepatology
researchProduct

Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrho…

2018

Background: In 2012, an Italian Named Patient Program began for hepatitis C virus (HCV)-infected liver transplant (LT) recipients with advanced fibrosis, before approval of direct antiviral agents (DAA), to benefit severely ill patients. The aim of this “real-life” study was to assess treatment efficacy and safety with an extended course of daclatasvir (DCV) plus sofosbuvir (SOF) with or without ribavirin (RBV). Methods: All HCV LT recipients with severe fibrosis in 15 Italian transplant centers were treated with DCV+SOF±RBV for 24 weeks; sustained virological response was assessed at 12 weeks post-treatment (SVR12). Results: Eighty-seven patients were enrolled (75.9% males, mean age 58.4 ±…

Liver CirrhosisMalehepatitis C virusPyrrolidinesCirrhosisSofosbuvirmedicine.medical_treatmentantiviral treatmentHepacivirus030230 surgeryLiver transplantationmedicine.disease_causeGastroenterologychemistry.chemical_compound0302 clinical medicineRecurrencehepatitis C viruProspective StudiesProspective cohort studySettore MED/12 - Gastroenterologialiver transplantationdirect antiviral agentsImidazolesValineHepatitis CMiddle AgedPrognosisHepatitis CItalyHCVDrug Therapy CombinationFemale030211 gastroenterology & hepatologymedicine.drugmedicine.medical_specialtyDaclatasvirHepatitis C virusAntiviral Agentsantiviral treatment; cirrhosis; direct antiviral agents; hepatitis C virus; liver transplantation03 medical and health sciencesInternal medicineRibavirinmedicineHumansTransplantationdirect antiviral agentbusiness.industryRibavirincirrhosismedicine.diseasechemistryCarbamatesSofosbuvirbusinessFollow-Up Studiescirrhosi
researchProduct

Efficacy of an escalating dose regimen of pegylated interferon ?-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation

2007

We evaluated the safety and efficacy of an escalating dose regimen of pegylated interferon alpha-2a (PEG-IFN(alpha-2a)) and ribavirin in the early phase of recurrent hepatitis C after orthotopic liver transplantation (OLT). In this prospective study, 26 patients transplanted for hepatitis C virus cirrhosis with recurrent hepatitis C were treated 3.4 +/- 3.6 months after OLT and compared with an untreated historical control. PEG-IFN(alpha-2a) was initiated as monotherapy, following stepwise dose escalation up to 180 mug/week and the addition of ribavirin up to 1200 mg/day or maximally tolerated doses for 48 weeks. In the intent-to-treat analysis, 38% showed an early virological response (EVR…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatmentHepacivirusLiver transplantationInterferon alpha-2medicine.disease_causeGastroenterologyAntiviral AgentsPolyethylene GlycolsCohort Studieschemistry.chemical_compoundPostoperative ComplicationsPegylated interferonRecurrenceInternal medicineRibavirinmedicineHumansAdverse effectAgedTransplantationbusiness.industryRibavirinInterferon-alphaAlanine TransaminaseHepatitis CMiddle Agedmedicine.diseaseHepatitis CRecombinant ProteinsLiver TransplantationRegimenTreatment OutcomechemistryImmunologyRNA ViralFemalebusinessmedicine.drugTransplant International
researchProduct

Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing Strategies

2020

INTRODUCTION: Despite the negative impact of covert hepatic encephalopathy on the outcome of patients with liver cirrhosis, data regarding the ability of different testing strategies to predict overt hepatic encephalopathy (OHE) development and mortality are limited. This study aimed to compare the ability of Psychometric Hepatic Encephalopathy Score (PHES), critical flicker frequency (CFF), simplified animal naming test (S-ANT1), and clinical covert hepatic encephalopathy (CCHE) score to predict OHE development and mortality. METHODS: A total of 224 patients with liver cirrhosis were tested with different testing strategies and prospectively followed up regarding clinically relevant outcom…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisPsychometricsmedicine.medical_treatmentKaplan-Meier EstimateLiver transplantationRisk AssessmentSeverity of Illness IndexArticleEnd Stage Liver Disease03 medical and health sciencesLiver disease0302 clinical medicinePredictive Value of TestsInternal medicineSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyHepatic encephalopathyAgedReceiver operating characteristicbusiness.industryGastroenterologyMiddle Agedmedicine.diseasePrognosisLiverROC Curve030220 oncology & carcinogenesisPredictive value of testsHepatic EncephalopathyFeasibility Studies030211 gastroenterology & hepatologyFemalebusinessFollow-Up StudiesClinical and Translational Gastroenterology
researchProduct

Liver stiffness measurement in patients with nodular regenerative hyperplasia undergoing magnetic resonance elastography

2020

Purpose Nodular regenerative hyperplasia (NRH) may mimic cirrhosis at imaging. We aim to investigate the effect of NRH on liver stiffness measurement (LSM) obtained with magnetic resonance elastography (MRE).Methods This retrospective, Institutional Review Board-approved study included 37 subjects with NRH (Group 1) and no or minimal fibrosis (F0-F1), a control group (Group 2) made of 30 subjects with non-advanced fibrosis (F0-F2), and a control group (Group 3) made of 30 subjects with advanced fibrosis (F3-F4), all with available MRE. LSM was measured in each subject along with assessment of hepatic morphological features of cirrhosis and signs of portal hypertension. The significance of t…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisUrologyContrast MediaGastroenterology030218 nuclear medicine & medical imagingDiagnosis Differential03 medical and health sciencessymbols.namesakeMeglumineMagnetic resonance imaging0302 clinical medicineFibrosisInternal medicineOrganometallic CompoundsmedicineHumansRadiology Nuclear Medicine and imagingFisher's exact testAgedRetrospective StudiesHyperplasiaRadiological and Ultrasound Technologymedicine.diagnostic_testNodular regenerative hyperplasiabusiness.industryGastroenterologyMagnetic resonance imagingMiddle AgedHepatologymedicine.diseaseLiver RegenerationLiver TransplantationMagnetic resonance elastographyLiverMagnetic resonance elastography030220 oncology & carcinogenesissymbolsElasticity Imaging TechniquesPortal hypertensionFemalebusinessLiver diseaseNodular regenerative hyperplasiaAbdominal Radiology
researchProduct

Hemodynamic changes in splanchnic circulation after orthotopic liver transplantation in patients with liver cirrhosis

2002

Background: Liver cirrhosis increases portal vein pressure and alters the splanchnic circulation. With Doppler sonography, we investigated the hemodynamic changes in the portal vein, superior mesenteric artery, hepatic and splenic arteries and spleen size in a group of patients with end-stage liver disease before and after orthotopic liver transplantation (OLT). Methods: Ten patients (seven male, three female; mean age = 48.8 ± 7.6 years) who underwent OLT for liver cirrhosis mainly associated with hepatitis C virus infection completed the study. The control group consisted of 10 patients matched by sex and age who had no gastroenterologic or vascular diseases. All patients underwent duplex…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisUrologyPortal venous pressuremedicine.medical_treatmentHepatic VeinsSplenic arteryLiver transplantationLiver cirrhosiLiver diseaseMesenteric Artery SuperiorInternal medicinemedicine.arteryHumansMedicineRadiology Nuclear Medicine and imagingSplanchnic CirculationUltrasonography Doppler ColorDuplex DopplerFibrous capsule of GlissonRadiological and Ultrasound TechnologyPortal Veinbusiness.industrySplanchnic CirculationHemodynamic changeGastroenterologyGeneral MedicineMiddle Agedmedicine.diseaseLiver TransplantationSurgeryTransplantationsurgical procedures operativecardiovascular systemCardiologyFemaleVascular ResistancebusinessSplenic ArteryBlood Flow VelocitySpleenAbdominal Imaging
researchProduct

Cytomegalovirus reactivation in liver transplant recipients due to hepatitis C cirrhosis is associated with higher cardiovascular risk - an observati…

2017

The association between cytomegalovirus (CMV) reactivation and cardiovascular risk has been reported in solid organ transplant populations; however, it has yet to be assessed in liver transplantation (LT). We aim to evaluate whether CMV reactivation is associated with cardiovascular events (CVE) in HCV-LT patients. LT patients (2010 and 2014) due to HCV cirrhosis were included. Clinically significant CMV (CS-CMV) was defined as viral load (VL) >5000 copies/ml, need of therapy or CMV disease. Baseline variables and endpoint measures (CVE, survival, severe recurrent hepatitis C, de novo tumors, and diabetes) were collected. One hundred and forty patients were included. At LT, a history of AHT…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentCongenital cytomegalovirus infectionCytomegalovirus030230 surgeryLiver transplantationGastroenterology03 medical and health sciences0302 clinical medicineRisk FactorsDiabetes mellitusInternal medicinemedicineHumansAgedProportional Hazards ModelsRetrospective StudiesImmunosuppression TherapyTransplantationProportional hazards modelbusiness.industryvirus diseasesRetrospective cohort studyHepatitis CMiddle AgedViral Loadmedicine.diseaseHepatitis CTissue DonorsLiver TransplantationCardiovascular DiseasesCytomegalovirus Infections030211 gastroenterology & hepatologyFemalebusinessViral loadGlomerular Filtration RateTransplant international : official journal of the European Society for Organ Transplantation
researchProduct

Validation of the Clinical Frailty Scale for the Prediction of Mortality in Patients With Liver Cirrhosis

2020

Introduction Frailty is a common but often underestimated complication in patients with liver cirrhosis. The Clinical Frailty Scale (CFS) allows the assessment of frailty within a short period of time but has only been investigated in a Canadian cohort of outpatients. The aim of the current study was to evaluate the ability of the CFS to predict mortality in outpatients and nonelectively hospitalized German patients. Methods Two hundred outpatients and 99 nonelectively hospitalized patients with liver cirrhosis were prospectively enrolled. Outpatients/inpatients were followed for a median of 364/28 days regarding the primary outcome of death or liver transplantation. Eighty-seven patients o…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentLiver transplantationMuscle massRisk AssessmentSeverity of Illness IndexArticle03 medical and health sciences0302 clinical medicineInternal medicineGermanymedicineHumansIn patientHospital MortalityProspective StudiesMuscle SkeletalAgedFrailtybusiness.industryHazard ratioGastroenterologyAcute-On-Chronic Liver FailureOdds ratioMiddle Agedmedicine.diseaseLiver TransplantationHospitalizationLiver030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatologyFemaleComplicationbusinessTomography X-Ray ComputedFollow-Up StudiesClinical and Translational Gastroenterology
researchProduct

Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites: A Meta-analysis of Individual Patient Data

2007

Several randomized controlled trials have compared a transjugular intrahepatic portosystemic shunt (TIPS) with large-volume paracentesis in cirrhotic patients with refractory ascites. Although all agree that TIPS reduces the recurrence rate of ascites, survival is controversial. The aim of this study was to compare the effects of TIPS and large-volume paracentesis in cirrhotic patients with refractory ascites by means of meta-analysis of individual patient data from 4 randomized controlled trials.The study population consisted of 305 patients: 149 allocated to TIPS and 156 to paracentesis. Cumulative probabilities of transplant-free survival and of hepatic encephalopathy (HE) were estimated…

Liver CirrhosisMalemedicine.medical_specialtymedicine.medical_treatmentKaplan-Meier EstimateGastroenterologySpontaneous bacterial peritonitisModel for End-Stage Liver DiseaseHepatorenal syndromeRisk FactorsInternal medicineAscitesmedicineParacentesisHumansParacentesisHepatic encephalopathyAgedFirst episodeHepatologymedicine.diagnostic_testbusiness.industrySodiumGastroenterologyAscitesBilirubinPatient dataMiddle Agedmedicine.diseaseLiver TransplantationSurgeryTreatment OutcomeMeta-analysisHepatic EncephalopathyRegression AnalysisFemaleRefractory ascitesPortasystemic Shunt Transjugular Intrahepaticmedicine.symptombusinessTransjugular intrahepatic portosystemic shuntGastroenterology
researchProduct